Literature DB >> 23974095

Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway.

Bruna Corominas-Faja1, Sílvia Cufí, Cristina Oliveras-Ferraros, Elisabet Cuyàs, Eugeni López-Bonet, Ruth Lupu, Tomás Alarcón, Luciano Vellon, Juan Manuel Iglesias, Olatz Leis, Ángel G Martín, Alejandro Vazquez-Martin, Javier A Menendez.   

Abstract

Energy metabolism plasticity enables stemness programs during the reprogramming of somatic cells to an induced pluripotent stem cell (iPSC) state. This relationship may introduce a new era in the understanding of Warburg's theory on the metabolic origin of cancer at the level of cancer stem cells (CSCs). Here, we used Yamanaka's stem cell technology in an attempt to create stable CSC research lines in which to dissect the transcriptional control of mTOR--the master switch of cellular catabolism and anabolism--in CSC-like states. The rare colonies with iPSC-like morphology, obtained following the viral transduction of the Oct4, Sox2, Klf4, and c-Myc (OSKM) stemness factors into MCF-7 luminal-like breast cancer cells (MCF-7/Rep), demonstrated an intermediate state between cancer cells and bona fide iPSCs. MCF-7/Rep cells notably overexpressed SOX2 and stage-specific embryonic antigen (SSEA)-4 proteins; however, other stemness-related markers (OCT4, NANOG, SSEA-1, TRA-1-60, and TRA-1-81) were found at low to moderate levels. The transcriptional analyses of OSKM factors confirmed the strong but unique reactivation of the endogenous Sox2 stemness gene accompanied by the silencing of the exogenous Sox2 transgene in MCF-7/Rep cells. Some but not all MCF-7/Rep cells acquired strong alkaline phosphatase (AP) activity compared with MCF-7 parental cells. SOX2-overexpressing MCF-7/Rep cells contained drastically higher percentages of CD44(+) and ALDEFLUOR-stained ALDH(bright) cells than MCF-7 parental cells. The overlap between differentially expressed mTOR signaling-related genes in 3 different SOX2-overexpressing CSC-like cell lines revealed a notable downregulation of 3 genes, PRKAA1 (which codes for the catalytic α 1 subunit of AMPK), DDIT4/REDD1 (a stress response gene that operates as a negative regulator of mTOR), and DEPTOR (a naturally occurring endogenous inhibitor of mTOR activity). The insulin-receptor gene (INSR) was differentially upregulated in MCF-7/Rep cells. Consistent with the downregulation of AMPK expression, immunoblotting procedures confirmed upregulation of p70S6K and increased phosphorylation of mTOR in Sox2-overexpressing CSC-like cell populations. Using an in vitro model of the de novo generation of CSC-like states through the nuclear reprogramming of an established breast cancer cell line, we reveal that the transcriptional suppression of mTOR repressors is an intrinsic process occurring during the acquisition of CSC-like properties by differentiated populations of luminal-like breast cancer cells. This approach may provide a new path for obtaining information about preventing the appearance of CSCs through the modulation of the AMPK/mTOR pathway.

Entities:  

Keywords:  AMPK; SOX2; breast cancer; cancer stem cells; mTOR; reprogramming

Mesh:

Substances:

Year:  2013        PMID: 23974095      PMCID: PMC3875684          DOI: 10.4161/cc.26173

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  99 in total

1.  DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival.

Authors:  Timothy R Peterson; Mathieu Laplante; Carson C Thoreen; Yasemin Sancak; Seong A Kang; W Michael Kuehl; Nathanael S Gray; David M Sabatini
Journal:  Cell       Date:  2009-05-14       Impact factor: 41.582

2.  A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity.

Authors:  Rosa M Marión; Katerina Strati; Han Li; Matilde Murga; Raquel Blanco; Sagrario Ortega; Oscar Fernandez-Capetillo; Manuel Serrano; Maria A Blasco
Journal:  Nature       Date:  2009-08-09       Impact factor: 49.962

3.  The role of p53 in limiting somatic cell reprogramming.

Authors:  Yan Liu; Ruben Hoya-Arias; Stephen D Nimer
Journal:  Cell Res       Date:  2009-11-02       Impact factor: 25.617

4.  Immortalization eliminates a roadblock during cellular reprogramming into iPS cells.

Authors:  Jochen Utikal; Jose M Polo; Matthias Stadtfeld; Nimet Maherali; Warakorn Kulalert; Ryan M Walsh; Adam Khalil; James G Rheinwald; Konrad Hochedlinger
Journal:  Nature       Date:  2009-08-09       Impact factor: 49.962

5.  Linking the p53 tumour suppressor pathway to somatic cell reprogramming.

Authors:  Teruhisa Kawamura; Jotaro Suzuki; Yunyuan V Wang; Sergio Menendez; Laura Batlle Morera; Angel Raya; Geoffrey M Wahl; Juan Carlos Izpisúa Belmonte
Journal:  Nature       Date:  2009-08-09       Impact factor: 49.962

6.  Octamer 4 small interfering RNA results in cancer stem cell-like cell apoptosis.

Authors:  Tingsong Hu; Shanrong Liu; Deborah R Breiter; Fang Wang; Ying Tang; Shuhan Sun
Journal:  Cancer Res       Date:  2008-08-15       Impact factor: 12.701

Review 7.  The tumorigenicity of human embryonic stem cells.

Authors:  Barak Blum; Nissim Benvenisty
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

8.  Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes.

Authors:  Trond Aasen; Angel Raya; Maria J Barrero; Elena Garreta; Antonella Consiglio; Federico Gonzalez; Rita Vassena; Josipa Bilić; Vladimir Pekarik; Gustavo Tiscornia; Michael Edel; Stéphanie Boué; Juan Carlos Izpisúa Belmonte
Journal:  Nat Biotechnol       Date:  2008-10-17       Impact factor: 54.908

9.  The anti-apoptotic gene survivin contributes to teratoma formation by human embryonic stem cells.

Authors:  Barak Blum; Ori Bar-Nur; Tamar Golan-Lev; Nissim Benvenisty
Journal:  Nat Biotechnol       Date:  2009-03-01       Impact factor: 54.908

Review 10.  Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine.

Authors:  Paul S Knoepfler
Journal:  Stem Cells       Date:  2009-05       Impact factor: 6.277

View more
  57 in total

1.  Rapamycin induces pluripotent genes associated with avoidance of replicative senescence.

Authors:  Tatiana V Pospelova; Tatiana V Bykova; Svetlana G Zubova; Natalia V Katolikova; Natalia M Yartzeva; Valery A Pospelov
Journal:  Cell Cycle       Date:  2013-12-02       Impact factor: 4.534

Review 2.  PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application.

Authors:  Pu Xia; Xiao-Yan Xu
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

3.  Xenopatients 2.0: reprogramming the epigenetic landscapes of patient-derived cancer genomes.

Authors:  Javier A Menendez; Tomás Alarcón; Bruna Corominas-Faja; Elisabet Cuyàs; Eugeni López-Bonet; Angel G Martin; Luciano Vellon
Journal:  Cell Cycle       Date:  2014-01-09       Impact factor: 4.534

4.  Patient-derived induced pluripotent stem cells in cancer research and precision oncology.

Authors:  Eirini P Papapetrou
Journal:  Nat Med       Date:  2016-12-06       Impact factor: 53.440

5.  Novel AKT phosphorylation sites identified in the pluripotency factors OCT4, SOX2 and KLF4.

Authors:  Peter N Malak; Benjamin Dannenmann; Alexander Hirth; Oliver C Rothfuss; Klaus Schulze-Osthoff
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 6.  Metformin may function as anti-cancer agent via targeting cancer stem cells: the potential biological significance of tumor-associated miRNAs in breast and pancreatic cancers.

Authors:  Bin Bao; Asfar S Azmi; Shadan Ali; Feras Zaiem; Fazlul H Sarkar
Journal:  Ann Transl Med       Date:  2014-06

Review 7.  Metabolic control of cancer cell stemness: Lessons from iPS cells.

Authors:  Javier A Menendez
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 8.  Current status in cancer cell reprogramming and its clinical implications.

Authors:  Kenan Izgi; Halit Canatan; Banu Iskender
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-12       Impact factor: 4.553

Review 9.  Application of induced pluripotency in cancer studies.

Authors:  Patrycja Czerwińska; Sylwia Mazurek; Maciej Wiznerowicz
Journal:  Rep Pract Oncol Radiother       Date:  2018-04-24

10.  Reprogramming of non-genomic estrogen signaling by the stemness factor SOX2 enhances the tumor-initiating capacity of breast cancer cells.

Authors:  Alejandro Vazquez-Martin; Sílvia Cufí; Eugeni López-Bonet; Bruna Corominas-Faja; Elisabet Cuyàs; Luciano Vellon; Juan Manuel Iglesias; Olatz Leis; Angel G Martín; Javier A Menendez
Journal:  Cell Cycle       Date:  2013-10-04       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.